Revenue grew 8.55% to CNY 6.08 billion in 2024, with net profit up 1.19% and gross margin rising to 49.47%. Strategic M&A, digital transformation, and strong R&D investment supported growth, while risks include policy, M&A, and laboratory investment uncertainties.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.